See the DrugPatentWatch profile for cosentyx

Based on the information provided, I was unable to find that Cosentyx (secukinumab) specifically requires heart tests before use. However, it is essential to note that, like any other medication, a patient's overall health, including cardiovascular health, should be evaluated before starting Cosentyx. This evaluation might include heart tests, depending on the patient's medical history and the prescribing physician's discretion.

Cosentyx is a prescription medication used to treat various conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is a monoclonal antibody that targets interleukin-17A (IL-17A), a cytokine involved in inflammatory and immune responses.

For more information on Cosentyx, consult the drug's official website or the prescribing information provided by the manufacturer. For insights on drug patents and related information, you can visit DrugPatentWatch.com.

Sources:
1. Cosentyx (secukinumab) [Prescribing Information]. (2021). Novartis Pharmaceuticals Corporation. https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf
2. Cosentyx. (n.d.). Novartis. https://www.cosentyx.com/
3. DrugPatentWatch. Cosentyx (secukinumab) Drug Patent Insight. https://www.drugpatentwatch.com/drugs/cosentyx